Bellerophon Therapeutics
Presença
Bellerophon Therapeutics é uma empresa listada sob o símbolo BLPH (US).
Executivos
Veja o organograma con seus 5 executivos principais
Biografias mais buscadas da Bellerophon Therapeutics
- Peter Fernandes, Chief Executive Officer
- Scott Bruder, Director
- Mary Ann Cloyd, Independent Director
Criar um alerta
para seguir os movimentos de executivos da Bellerophon Therapeutics.
Biotecnologia
Bellerophon Therapeutics possui 2.282 concorrentes concorrentes Lonza (Suíça), Eurofins (Luxemburgo) e Adaptive Phage Therapeutics (Estados Unidos).
Popular M&A news in Biotecnologia
- Endeavor BioMedicines acaba de anunciar uma arrecadação de fundos de 132 milhões de dólares. (publicado em 25 de abril de 2024).
- Metsera acaba de anunciar uma arrecadação de fundos de 290 milhões de dólares. (publicado em 23 de abril de 2024).
- Histogen has filed for bankruptcy protection (publicado em 19 de abril de 2024).
Outros contatos sugeridos na indústria do Biotecnologia
Notícias
Últimos comunicados de imprensa de Bellerophon Therapeutics
- Press Releases | Bellerophon Therapeutics, Inc.
- Bellerophon Announces Positive Top-line Results from Cohort 2 of Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease | Bellerophon Therapeutics, Inc.
- Bellerophon Announces Positive Initial Data from Acute Hemodynamic Dose Escalation Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease | Bellerophon Therapeutics, Inc.
- Bellerophon Presents New Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at Pulmonary Fibrosis Foundation Summit 2019 | Bellerophon Therapeutics, Inc.
- Bellerophon Provides Business Update and Reports Third Quarter 2019 Financial Results | Bellerophon Therapeutics, Inc.
- Bellerophon Presents New Positive Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at CHEST 2019 Annual Meeting | Bellerophon Therapeutics, Inc.
- Bellerophon to Present New Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at CHEST 2019 Annual Meeting | Bellerophon Therapeutics, Inc.
- Bellerophon Receives Orphan Drug Designation for Nitric Oxide in the Treatment of Idiopathic Pulmonary Fibrosis | Bellerophon Therapeutics, Inc.
- Bellerophon to Present at the H.C. Wainwright 21st Annual Global Investment Conference | Bellerophon Therapeutics, Inc.
- View more press releases Close
Redes sociais sobre Bellerophon Therapeutics
- Bellerophon Therapeutics na Wikipedia, Google News e Yahoo Finance
- Bellerophon Therapeutics na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo Peter Fernandes 
Ligue para a Bellerophon Therapeutics em +1 908...
